Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Mov Disord. 2019 Jan 17;:
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Mov Disord. 2018 Dec 21;:
J Neuroeng Rehabil. 2018 Nov 06;15(1):97
Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
Mov Disord. 2018 Oct;33(10):1560
Mov Disord Clin Pract. 2018 Jan-Feb;5(1):66-74
Ann Neurol. 2018 Oct 24;:
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
Eur J Neurosci. 2018 Sep 30;:
Neuropharmacology. 2018 Jun 01;:
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
Parkinsonism Relat Disord. 2018 May 05;:
Curr Opin Neurol. 2018 May 08;: